Analyst Whit Mayo of Leerink Partners reiterated a Buy rating on BrightSpring Health Services, Inc. (BTSG – Research Report), with a price target of $26.50.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Whit Mayo has given his Buy rating due to a combination of factors including BrightSpring Health Services, Inc.’s strong financial performance and promising future outlook. The company reported impressive first-quarter results for 2025, with revenue and EBITDA surpassing expectations by 6.1% and 6.6% respectively, leading to an upward revision of their 2025 outlook. This performance was driven by both the Pharmacy and Provider segments, with the Pharmacy segment showing particularly strong growth.
Additionally, BrightSpring Health Services, Inc. raised its EBITDA guidance by $25 million, indicating anticipated growth of 24-27%, which reinforces confidence in the company’s organic growth potential. The acquisition of certain assets from AMED is also expected to contribute positively, although further details are awaited. These factors collectively support Whit Mayo’s decision to maintain a Buy rating for BrightSpring Health Services, Inc.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $25.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue